HomeAboutMediaCareersSite MapContactSearch
Geron
PatientsProductsTechnology & ScienceInvestors
print
  • Telomerase Inhibitor Drug - GRN163L
  • Telomerase Cancer Vaccine - GRNVAC1/GRNVAC2
  • hESC-Derived Oligodendrocytes - GRNOPC1
  • hESC-Derived Cardiomyocytes - GRNCM1
  • hESC-Derived Islet Cells - GRNIC1
  • Osteoblasts
  • Chondrocytes
  • Hepatocytes

Product Information

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. We are advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. We are also the world leader in the development of human embryonic stem cell-based therapeutics, with our spinal cord injury treatment anticipated to be the first product to enter clinical development.

Visionary Therapeutics
Home | About | Media | Careers | Site Map | Contact | Search
Patients | Products | Technology & Science | Investors
Legal Disclaimer
Copyright © Geron 2008. All rights reserved.
Site design and layout by BFW Interactive